Molecular Partners AG announced that the Board of Directors has decided to propose Gwen Fyfe, MD, for election as member of the Board of Directors at the next Annual General Meeting on May 11, 2017. Gwen has more than 20 years of drug development experience in oncology. She held various positions at Genentech from 1997-2009, including vice president, oncology development, playing an important role in the development of Genentech's approved oncology agents including Rituxan®, Herceptin®, Avastin® and Tarceva®. Since leaving Genentech in 2009, she has been a consultant for venture capital firms and for a variety of biotechnology companies.